eLife (Oct 2020)

Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers

  • Tobias Lieblein,
  • Rene Zangl,
  • Janosch Martin,
  • Jan Hoffmann,
  • Marie J Hutchison,
  • Tina Stark,
  • Elke Stirnal,
  • Thomas Schrader,
  • Harald Schwalbe,
  • Nina Morgner

DOI
https://doi.org/10.7554/eLife.59306
Journal volume & issue
Vol. 9

Abstract

Read online

The formation of oligomers of the amyloid-β peptide plays a key role in the onset of Alzheimer's disease. We describe herein the investigation of disease-relevant small amyloid-β oligomers by mass spectrometry and ion mobility spectrometry, revealing functionally relevant structural attributes. In particular, we can show that amyloid-β oligomers develop in two distinct arrangements leading to either neurotoxic oligomers and fibrils or non-toxic amorphous aggregates. Comprehending the key-attributes responsible for those pathways on a molecular level is a pre-requisite to specifically target the peptide's tertiary structure with the aim to promote the emergence of non-toxic aggregates. Here, we show for two fibril inhibiting ligands, an ionic molecular tweezer and a hydrophobic peptide that despite their different interaction mechanisms, the suppression of the fibril pathway can be deduced from the disappearance of the corresponding structure of the first amyloid-β oligomers.

Keywords